Panel discussion 1

The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs. diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) [Erratum appears in JAMA 2004; 291(18): 2196] [Erratum appears in JAMA 2003; 289(2): 178]. JAMA 2002; 288(23): 2981–97.

Agency for Healthcare Research and Quality. Management of Uterine Fibroids: An Update of the Evidence. US Department of Health & Human Services, Rockville, MD, 2007.

Institute of Medicine (IOM). Initial National Priorities for Comparative Effectiveness Research. 30 June 2009 National Academies Press. Washington. DC.

Rawlins M . In pursuit of quality: The National Institute for Health and Clinical Excellence. Lancet 1999; 353(9158): 1079–82.

Ashton HA Buxton MJ Day NE Kim LG Marteau TM Scott RA Thompson SG Walker NM ; Multicentre Aneurysm Screening Study Group, (MASS). into the effect of abdominal aortic aneurysm screening on mortality in men: A randomized controlled trial. Lancet 2002; 360(9345): 1531–39.

Rossouw JE Anderson GL Prentice RL LaCroix AZ Kooperberg C Stefanick ML . Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the women’s health initiative randomized controlled trial. JAMA 2002; 288(3): 321–33.